10-Q: Nuwellis Reports First Quarter 2024 Results Amidst Cost-Cutting Measures and Capital Raise

Nuwellis, Inc. reports a net loss for Q1 2024, while implementing cost-cutting measures and securing additional funding through a public offering.

Summary

• Nuwellis, Inc. reported a net loss of $4.33 million for the first quarter of 2024, compared to a net loss of $6.485 million in the same period of 2023.
• The company's net sales increased slightly to $1.857 million from $1.826 million year-over-year.
• Operating expenses decreased to $5.94 million from $6.918 million in the prior year, driven by reductions in selling, general, and administrative expenses, as well as research and development costs.
• The company has implemented cost-cutting measures, including job eliminations, salary reductions for senior management, and a temporary suspension of the company's 401k match, to reduce its monthly cash burn rate by approximately 40%.
• Nuwellis completed a public offering on April 30, 2024, raising approximately $2.1 million in net proceeds.
• The company's cash and cash equivalents decreased to $1.4 million as of March 31, 2024, from $3.8 million at the end of 2023.
• The company believes its existing capital resources will be sufficient to support its operating plan through August 31, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive signs, such as a decrease in net loss and operating expenses, the company's financial position remains precarious, with a low cash balance and the need for additional funding. The risk of delisting and the legal claim add to the negative sentiment.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Operating expenses were reduced, reflecting cost-cutting efforts.
• Net sales saw a slight increase, driven by higher circuit sales and international revenue.
• The company successfully raised additional capital through a public offering.
• The company has taken steps to reduce its monthly cash burn rate by approximately 40%.

Negatives

• The company continues to operate at a loss, with a net loss of $4.33 million for Q1 2024.
• Cash and cash equivalents decreased significantly from $3.8 million to $1.4 million during the quarter.
• The company's existing capital resources are only expected to support operations through August 31, 2024.
• The company has implemented cost-cutting measures, including job eliminations and salary reductions, which may impact employee morale and productivity.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• There is no assurance that the company will be able to raise additional capital on favorable terms or at all.
• The company's stock may be delisted from Nasdaq if it does not regain compliance with the minimum bid price requirement by June 4, 2024.
• The company is facing a legal claim from SeaStar Medical Holding Corporation for breach of payment obligations.
• The company has identified material weaknesses in its internal controls over financial reporting.

Future Outlook

The company expects to incur additional losses in the near-term as it grows the Aquadex Business. The company believes that its existing capital resources will be sufficient to support its operating plan through August 31, 2024, but will seek to raise additional capital to support its growth or other strategic initiatives through debt, equity or a combination thereof.

Management Comments

• The company has recently undertaken steps to reduce our monthly cash burn rate, balanced against our strategic growth initiatives, which will provide more flexibility in anticipation of tougher capital market conditions for microcap companies like Nuwellis.
• The company believes that its existing capital resources will be sufficient to support its operating plan through August 31, 2024.

Industry Context

The company operates in the medical technology sector, specifically focusing on fluid overload management. The company's Aquadex system competes with other therapies and devices used for ultrafiltration. The company's recent collaboration with DaVita indicates a strategic move to expand its market reach in both hospital and outpatient settings.

Comparison to Industry Standards

• Nuwellis's revenue of $1.857 million for the quarter is relatively low compared to larger medical device companies, such as Baxter International, which reported billions in revenue.
• The company's net loss of $4.33 million is not uncommon for early-stage medical device companies that are still in the commercialization phase.
• The company's cost-cutting measures are a common strategy for companies facing financial challenges, similar to other microcap companies in the medical device sector.
• The company's reliance on equity financing is typical for companies in this stage, but it also highlights the need for a clear path to profitability.
• The company's collaboration with DaVita is a positive step, but its success will depend on the adoption of the Aquadex system in DaVita's network, which is similar to other medical device companies that partner with large healthcare providers.

Legal Proceedings

• On April 4, 2024, the company received a written notice from SeaStar Medical Holding Corporation alleging the company has breached its payment obligations arising under a License and Distribution Agreement.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential delisting of the company's stock.
• Employees may be affected by job eliminations and salary reductions.
• Customers may be impacted by the company's financial instability and potential changes in operations.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to monitor the closing bid price of its common stock to regain compliance with Nasdaq listing requirements.
• The company will seek to raise additional capital to support its growth or other strategic initiatives.
• The company will continue to implement cost-cutting measures to reduce its monthly cash burn rate.
• The company will continue discussions with SeaStar Medical Holding Corporation to resolve the alleged breach of payment obligations.

Key Dates

Keywords

Nuwellis, Aquadex, ultrafiltration, medical technology, financial results, net loss, operating expenses, cost cutting, capital raise, public offering, cash burn, going concern, Nasdaq, Series J Convertible Preferred Stock, warrants